Protocol for the Examination of Specimens from Patients with Invasive Carcinoma of Renal Tubular Origin

Wilms tumors and tumors of urothelial origin are not included.

Version: Kidney 3.3.0.0 Protocol Posting Date: February 2017
Includes pTNM requirements from the 7th Edition, AJCC Staging Manual

Procedures
• Biopsy (Needle or Wedge)
• Partial Nephrectomy
• Radical Nephrectomy

Accreditation Requirements
This protocol can be utilized for a variety of procedures and tumor types for clinical care purposes. For accreditation purposes only, the definitive primary cancer resection specimen is required to have the core and conditional data elements reported in a synoptic format.

• Core data elements are required in reports to adequately describe appropriate malignancies. For accreditation purposes, essential data elements must be reported in all instances, even if the response is "not applicable" or "cannot be determined".
• Conditional data elements are only required to be reported if applicable as delineated in the protocol. For instance, the total number of lymph nodes examined must be reported, but only if nodes are present in the specimen.
• Optional data elements are identified with "+" and although not required for CAP accreditation purposes, may be considered for reporting as determined by local practice standards.

The use of this protocol is not required for recurrent tumors or for metastatic tumors that are resected at a different time than the primary tumor. Use of this protocol is also not required for pathology reviews performed at a second institution (ie, secondary consultation, second opinion, or review of outside case at second institution).

CAP Laboratory Accreditation Program Protocol Required Use Date: November 2017*
* Beginning January 1, 2018, the 8th edition AJCC Staging Manual should be used for reporting pTNM. The CAP will offer a revised 8th edition version of this protocol by mid-year 2017.

Authors
John R. Srigley MD*, Ming Zhou MD PhD*, Mahul B. Amin MD, Steven C. Campbell MD PhD, Anthony Chang MD, Brett Delahunt MD, David J. Grignon MD, Peter A. Humphrey MD PhD, Bradley C. Leibovich MD, Rodolfo Montironi MD, Andrew A. Renshaw MD, Victor E. Reuter MD
With guidance from the CAP Cancer and CAP Pathology Electronic Reporting Committees.
* Denotes primary author. All other contributing authors are listed alphabetically.
CAP Kidney Protocol Revision History

Summary of Changes
The following changes have been made since the October 2013 release.

Biopsy
The following data elements were modified:
- Procedure
- Histologic Type
- Sarcomatoid Features
- Histologic Grade

The following data elements were added:
- Rhabdoid Features
- Necrosis
- Lymphovascular Invasion

Nephrectomy, Partial or Radical
The following data elements were modified:
- Procedure
- Histologic Type
- Sarcomatoid Features
- Histologic Grade
- Microscopic Tumor Extension and Macroscopic Extent of Tumor (changed to Anatomic Extent of Tumor)
- Margins

The following data elements were added:
- Specimen
- Rhabdoid Features
- Tumor Necrosis
- Lymph Node Status (was previously under Pathologic Staging)

The following data elements were deleted:
- Microscopic Tumor Extension
- Macroscopic Extent of Tumor
Surgical Pathology Cancer Case Summary

Protocol posting date: February 2017

KIDNEY: Biopsy

Note: Use of case summary for biopsy specimens is optional.

Select a single response unless otherwise indicated.

+ Procedure
  + ___ Needle biopsy
  + ___ Incisional biopsy, wedge
  + ___ Other (specify): ___________________________
  + ___ Not specified

+ Specimen Laterality
  + ___ Right
  + ___ Left
  + ___ Not specified

+ Histologic Type (select all that apply) (Note A)
  + ___ Clear cell renal cell carcinoma
  + ___ Multilocular clear cell renal cell neoplasm of low malignant potential
  + ___ Papillary renal cell carcinoma
    + ___ Type 1
    + ___ Type 2
  + ___ Chromophobe renal cell carcinoma
  + ___ Collecting duct carcinoma
  + ___ Renal medullary carcinoma
  + ___ MiT family translocation renal cell carcinoma
    + ___ Xp11 translocation renal cell carcinoma
    + ___ t(6;11) renal cell carcinoma
    + ___ Other (specify): ___________________________
  + ___ Mucinous tubular and spindle renal cell carcinoma
  + ___ Tubulocystic renal cell carcinoma
  + ___ Acquired cystic disease associated renal cell carcinoma
  + ___ Clear cell papillary renal cell carcinoma
  + ___ Hereditary leiomyomatosis and renal cell carcinoma-associated renal cell carcinoma
  + ___ Succinate dehydrogenase (SDH) deficient renal cell carcinoma
  + ___ Renal cell carcinoma, unclassified
  + ___ Other (specify): ___________________________

+ Sarcomatoid Features (Note B)
  + ___ Not identified
  + ___ Present
    + Specify percentage of sarcomatoid element: _____%

+ Rhabdoid Features (Note B)
  + ___ Not identified
  + ___ Present

+ Histologic Grade (World Health Organization [WHO] / International Society of Urological Pathology [ISUP] Grade) (Note C)
  + ___ Not applicable

+ Data elements preceded by this symbol are not required for accreditation purposes. These optional elements may be clinically important but are not yet validated or regularly used in patient management.
+ ___ GX: Cannot be assessed
+ ___ G1: Nucleoli absent or inconspicuous and basophilic at 400x magnification
+ ___ G2: Nucleoli conspicuous and eosinophilic at 400x magnification, visible but not prominent at 100x magnification
+ ___ G3: Nucleoli conspicuous and eosinophilic at 100x magnification
+ ___ G4: Extreme nuclear pleomorphism and/or multinuclear giant cells and/or rhabdoid and/or sarcomatoid differentiation

+ Necrosis (Note D)
+ ___ Not identified
+ ___ Present

+ Lymphovascular Invasion
+ ___ Not identified
+ ___ Present

+ Additional Pathologic Findings
+ ___ None identified
+ ___ Other pathology present (specify): ___________________________

+ Comment(s)
Surgical Pathology Cancer Case Summary

Protocol posting date: February 2017

KIDNEY: Nephrectomy, Partial, Total, or Radical

Select a single response unless otherwise indicated.

Specimen (select all that apply)
___ Kidney
___ Ureter
___ Adrenal gland
___ Other (specify): __________________________

Specimen Laterality
___ Right
___ Left
___ Not specified

Procedure (Note E)
___ Partial nephrectomy
___ Radical nephrectomy
___ Total nephrectomy
___ Other (specify): __________________________
___ Not specified

+ Tumor Site (select all that apply)
  + ___ Upper pole
  + ___ Middle
  + ___ Lower pole
  + ___ Other (specify): __________________________
  + ___ Not specified

Tumor Size (largest tumor if multiple)
Greatest dimension: ___ cm
+ Additional dimensions: ___ x ___ cm
___ Cannot be determined (explain): ___________________

Tumor Focality
___ Unifocal
___ Multifocal

Histologic Type (select all that apply) (Note A)
___ Clear cell renal cell carcinoma
___ Multilocular clear cell renal cell neoplasm of low malignant potential
___ Papillary renal cell carcinoma
   ___ Type 1
   ___ Type 2
___ Chromophobe renal cell carcinoma
___ Collecting duct carcinoma
___ Renal medullary carcinoma
___ MiT family translocation renal cell carcinoma
 ___ Xp11 translocation renal cell carcinoma
 ___ t(6;11) renal cell carcinoma
___ Other (specify): __________________________

+ Data elements preceded by this symbol are not required for accreditation purposes. These optional elements may be clinically important but are not yet validated or regularly used in patient management.
____ Mucinous tubular and spindle renal cell carcinoma
____ Tubulocystic renal cell carcinoma
____ Acquired cystic disease associated renal cell carcinoma
____ Clear cell papillary renal cell carcinoma
____ Hereditary leiomyomatosis and renal cell carcinoma-associated renal cell carcinoma
____ Succinate dehydrogenase (SDH) deficient renal cell carcinoma
____ Renal cell carcinoma, unclassified
____ Other (specify): ____________________________

Sarcomatoid Features (Note B)
____ Not identified
____ Present
   + Specify percentage of sarcomatoid element: ____%

Rhabdoid Features (Note B)
____ Not identified
____ Present

Histologic Grade (WHO / ISUP Grade) (Note C)
____ Not applicable
____ GX: Cannot be assessed
____ G1: Nucleoli absent or inconspicuous and basophilic at 400x magnification
____ G2: Nucleoli conspicuous and eosinophilic at 400x magnification, visible but not prominent at 100x magnification
____ G3: Nucleoli conspicuous and eosinophilic at 100x magnification
____ G4: Extreme nuclear pleomorphism and/or multi-nuclear giant cells and/or rhabdoid and/or sarcomatoid differentiation

Tumor Necrosis (any amount) (Note D)
____ Not identified
____ Present
   + Specify percentage of necrosis: ____%

Anatomic Extent of Tumor (select all that apply) (Notes F and G)
____ Primary tumor cannot be assessed
____ No evidence of primary tumor
____ Tumor limited to kidney
____ Tumor extension into perinephric tissue (beyond renal capsule)
____ Tumor extension into renal sinus
____ Tumor extension beyond Gerota’s fascia
____ Tumor extension into major vein (renal vein or its segmental branches, inferior vena cava)
____ Tumor extension into pelvicalyceal system
____ Tumor extension into adrenal gland
   ____ Direct invasion (T4)
   ____ Noncontiguous (M1)
____ Tumor extension into other organ(s)/structure(s) (specify): _____________
### Margins (select all that apply) (Note H)
- Cannot be assessed
- Uninvolved by invasive carcinoma
- Involved by invasive carcinoma
  - Renal parenchymal margin (partial nephrectomy only)
  - Renal capsular margin (partial nephrectomy only)
  - Perinephric fat margin
  - Renal sinus soft tissue margin
  - Gerota’s fascial margin
  - Renal vein margin
  - Ureteral margin
  - Other (specify): ____________________________

### Lymphovascular Invasion (excluding renal vein and its segmental branches and inferior vena cava)
- Not identified
- Present
- Cannot be determined

### Regional Lymph Nodes
- No lymph nodes submitted or found

#### Lymph Node Examination (required only if lymph nodes are present in the specimen)
- Number of Lymph Nodes Involved: ________
  - Number cannot be determined (explain): ____________________________
- Number of Lymph Nodes Examined: ________
  - Number cannot be determined (explain): ____________________________

#### Site(s) of Involved Lymph Nodes (specify): __________________
*Note: Sites may include hilar, precaval, interaortocaval, paracaval, retrocaval, preaortic, paraaortic, retroaortic, or other lymph nodes.

- Size of largest metastatic deposit (millimeter): ___ mm
  - Specify location: __________
- Size of largest lymph node involved (centimeter): ___ cm
  - Specify location: __________

### Pathologic Stage Classification (pTNM, AJCC 7th Edition) (Note I)

#### TNM Descriptors (required only if applicable) (select all that apply)
- m (multiple primary tumors)
- r (recurrent)
- y (posttreatment)

#### Primary Tumor (pT)
- pTX: Primary tumor cannot be assessed
- pT0: No evidence of primary tumor
- pT1: Tumor 7 cm or less in greatest dimension, limited to the kidney
  - pT1a: Tumor 4 cm or less in greatest dimension, limited to the kidney
  - pT1b: Tumor more than 4 cm but not more than 7 cm in greatest dimension, limited to the kidney
- pT2: Tumor more than 7 cm in greatest dimension, limited to the kidney
  - pT2a: Tumor more than 7 cm but less than or equal to 10 cm in greatest dimension, limited to the kidney
  - pT2b: Tumor more than 10 cm, limited to the kidney

+ Data elements preceded by this symbol are not required for accreditation purposes. These optional elements may be clinically important but are not yet validated or regularly used in patient management.
pT3: Tumor extends into major veins or perinephric tissues but not into the ipsilateral adrenal gland and not beyond Gerota’s fascia
   ___ pT3a: Tumor grossly extends into the renal vein or its segmental (muscle containing) branches, or tumor invades perirenal and/or renal sinus fat but not beyond Gerota’s fascia
   ___ pT3b: Tumor grossly extends into the vena cava below the diaphragm
   ___ pT3c: Tumor grossly extends into vena cava above the diaphragm or invades the wall of the vena cava
   ___ pT4: Tumor invades beyond Gerota’s fascia (including contiguous extension into the ipsilateral adrenal gland)

Regional Lymph Nodes (pN)
   ___ pNX: Regional lymph nodes cannot be assessed
   ___ pN0: No regional lymph node metastasis
   ___ pN1: Metastasis in regional lymph node(s)

Distant Metastasis (pM) (required only if applicable)
   ___ pM1: Distant metastasis
      Specify site(s), if known: ____________________________

Pathologic Findings in Nonneoplastic Kidney (select all that apply) (Note J)
   ___ Insufficient tissue
   Significant pathologic alterations:
      ___ None identified
      ___ Glomerular disease (specify type): ______________________
      ___ Tubulointerstitial disease (specify type): __________________
      ___ Vascular disease (specify type): ______________________
      ___ Other (specify): ______________________

+ Other Tumors and/or Tumor-like Lesions (select all that apply)
  + ___ Cyst(s) (specify type): ______________________
  + ___ Tubular (papillary) adenoma(s)
  + ___ Other (specify): ______________________

+ Comment(s)
Explanatory Notes

A. Histologic Type

The current World Health Organization (WHO) classification (2016) is based on the International Society of Urological Pathology (ISUP) Vancouver Classification of Renal Neoplasia 2012.1,2

Clear cell renal cell carcinoma
Multilocular clear cell renal cell neoplasm of low malignant potential
Papillary renal cell carcinoma
  Type 1
  Type 2
Chromophobe renal cell carcinoma
Collecting duct carcinoma
Renal medullary carcinoma
MIT family translocation renal cell carcinoma
Mucinous tubular and spindle cell carcinoma
Tubulocystic renal cell carcinoma
Acquired cystic disease associated renal cell carcinoma
Clear cell papillary/tubulopapillary renal cell carcinoma
Hereditary leiomyomatosis and renal cell carcinoma-associated renal cell carcinoma
Succinate dehydrogenase (SDH) deficient renal carcinoma
Renal cell carcinoma, unclassified
Papillary adenoma
Renal oncocytoa

Many subtypes of renal cell carcinoma, including many newly described variants, have differing clinical behaviors and prognosis.1-4 Additionally the usage of adjuvant therapy is related to tumor subtype.5 The concept of an emerging/provisional category of renal cell carcinoma was introduced in the 2012 ISUP Vancouver classification.2 These tumors, while appearing distinctive, had not been fully characterized morphologically or by ancillary techniques. This category in the 2016 WHO Classification includes the following entities: oncocytoid renal cell carcinoma (RCC) post-neuroblastoma, thyroid-like follicular RCC, anaplastic lymphoma kinase (ALK) rearrangement-associated RCC, and RCC with (angio) leiomyomatous stroma.1 For the purpose of the protocol, these emerging tumors should be classified under "other" and the name specified.

Occasionally more than 1 histologic type of carcinoma occurs within the same kidney specimen. Each tumor type should be separately recorded along with its associated prognostic factors.6

B. Sarcomatoid and Rhabdoid Features

Sarcomatoid carcinoma is not a specific morphogenetic subtype of renal cell carcinoma but is considered as a pattern of dedifferentiation.1,6-8 Sarcomatoid change in a renal cell carcinoma is associated with an adverse outcome.1,8 Sarcomatoid morphology may be found in any histologic subtypes of renal cell carcinomas, including clear cell, papillary, chromophobe, collecting duct, and other rare and unclassified subtypes.1,6-8 When the background carcinoma subtype is recognized, it should be specified under histologic type (see Note A). Pure sarcomatoid carcinoma or sarcomatoid carcinoma associated with epithelial elements that do not conform to usual renal carcinoma cell types should be considered as unclassified renal cell carcinoma. Sarcomatoid morphology is also incorporated into the WHO/ISUP grading system as grade 4.

There is some indication that the percentage of sarcomatoid component in a renal cell carcinoma has prognostic importance.6,8

Rhabdoid features, like sarcomatoid, are a characteristic of high-grade disease. Rhabdoid cells have abundant eosinophilic cytoplasm with an eccentric nucleus often with a prominent nucleolus.8-11 Rhabdoid changes are associated with an adverse outcome and in cases with rhabdoid morphology, about 25% of them also show sarcomatoid features.1 Rhabdoid morphology is an important component of the new WHO/ISUP grading system (grade 4).8
No solid evidence exists on the prognostic significance of the extent of rhabdoid morphology.¹

C. Histologic Grade
The WHO/ISUP grading system has supplanted the Fuhrman system as the grading standard.¹,⁸ This grading system has been validated for both clear cell and papillary renal cell carcinoma; however, it has not been validated for other RCC subtypes.¹²,¹³ Nevertheless, the WHO/ISUP grade may be included for descriptive purposes. Currently it is recommended that chromophobe renal cell carcinoma not be graded with the WHO/ISUP system. Details are shown below:

- Not applicable
- Grade X - Cannot be assessed
- Grade 1 - Nucleoli absent or inconspicuous and basophilic at 400x magnification
- Grade 2 - Nucleoli conspicuous and eosinophilic at 400x magnification, visible but not prominent at 100x magnification
- Grade 3 - Nucleoli conspicuous and eosinophilic at 100x magnification
- Grade 4 - Extreme nuclear pleomorphism and/or multinuclear giant cells and/or rhabdoid and/or sarcomatoid differentiation

Although the grading system does reference the tinctorial characteristics of the nucleoli, the determining feature is the nucleolar prominence. Grade should be assigned based on the single high-power field showing the greatest degree of pleomorphism.

D. Necrosis
Tumor necrosis is an important prognostic factor in renal cell carcinoma.⁸,¹⁴,¹⁵ It is recommended that both macroscopic and microscopic (coagulative) necrosis be recorded. The prognostic significance of necrosis independent of tumor stage has been identified in clear cell and chromophobe renal cell carcinoma.¹⁴ The prognostic significance of necrosis in papillary renal cell carcinoma is controversial. Large papillary carcinomas not uncommonly display cystic necrosis and yet don’t exhibit extra renal spread. Tumor necrosis as a prognostic factor cannot be assessed in a situation where patients have undergone presurgical arterial embolization.

At present, the prognostic significance of the extent of necrosis is unclear; however, it is recommended that this be recorded as a percentage.¹⁵

E. Specimen Type
A standard radical nephrectomy specimen consists of the entire kidney including the calyces, pelvis, and a variable length of ureter. The adrenal gland is usually removed en bloc with the kidney. The entire perirenal fatty tissue is removed to the level of Gerota’s fascia, a membranous structure that is similar to the consistency of the renal capsule that encases the kidney in perirenal fat. Variable lengths of the major renal vessels at the hilus are submitted.

Regional lymphadenectomy is not generally performed even with a radical nephrectomy. A few lymph nodes may occasionally, be seen in the renal hilus around major vessels. Other regional lymph nodes (eg, paracaval, para-aortic, and retroperineal) may be submitted separately.

A partial nephrectomy specimen may vary from a simple enucleation of the tumor to part of a kidney containing variable portions of calyceal or renal pelvic collecting system. The perirenal fat immediately overlying the resected portion of the kidney but not to a level of Gerota’s fascia is usually included.

F. Macroscopic Extent of Tumor
A careful gross analysis and description of tumor extension in a nephrectomy specimen is important and should guide blocking of tissue samples for histologic assessment.¹⁶ Careful documentation of the tumor extension beyond kidney into perinephric fat and Gerota’s fascia provides important staging information.¹⁷,¹⁸ Renal sinus involvement in renal cell carcinoma is an under-recognized phenomenon.¹⁸ The renal sinus is an important pathway of spread of renal cell carcinoma (Figure 1, A and B). The renal sinus should be carefully assessed and generously sampled in order to detect renal sinus fat and vessel involvement.¹⁶ There is evolving literature
suggesting that renal sinus involvement predicts a more aggressive outcome than peripheral perinephric fat invasion.\textsuperscript{20,21} When renal carcinoma involves adrenal gland, it is important to document whether the involvement is contiguous spread of tumor or a separate (noncontiguous) nodule of carcinoma, the latter representing metastatic disease (pM1) (Figure 2).\textsuperscript{17}

Figure 1. A, Diagram showing the renal sinus fat (S) and its rich venous system that envelops the collecting system. The renal capsule terminates (arrow) just inside the vestibule of the hilus. B, A renal malignancy is constrained by the renal capsule (arrow), yet no fibrous capsule impedes its growth into the vascular tissue of the renal sinus (curved arrows). From Bonsib et al.\textsuperscript{19} Reproduced with permission of the American Journal of Surgical Pathology. © 2000 Wolters Kluwer Health.
Figure 2. Diagram showing relationship between local tumor extension and pT designation. When a tumor shows direct invasion into the perirenal fat or renal sinus fat, it is designated as pT3a. A tumor that directly invades the adrenal gland is designated as pT4, while a tumor that shows discontinuous (noncontiguous) involvement of the adrenal gland is considered metastatic (M1).

G. Microscopic Tumor Extension
The microscopic documentation of extrarenal extension is critical in assigning a pT category in renal cell carcinoma. Invasion of perirenal fat is considered pT3a and invasion beyond Gerota’s fascia is a feature of pT4 disease.17

The renal sinus is an anatomical compartment separating the renal parenchyma from the upper collecting system (renal pelvis and calyces).16,19 In this area abundant adipose tissue, lymphatics, and thin walled veins are noted in the renal sinus. Clear cell renal cell carcinomas ≥7 cm in diameter show renal sinus invasion in greater than 90% of cases.20 In recent years, the definition of renal sinus involvement has been clarified and includes the following: (1) tumor in contact with renal sinus fat, (2) tumor in loose connective tissue of sinus clearly beyond the renal parenchyma, and (3) involvement of endothelial lined spaces (with or without mural smooth muscle), including lymphatics.16,22,23

Involvement of the renal vein or segmental branches is generally identified macroscopically and is definitional for the pT3a category.17 It is important to document renal involvement microscopically.

Direct spread of tumor into the adrenal gland (if present) is considered pT4 disease.24,25 However, if there is a discrete separate nodule in the adrenal gland, this would be considered pM1 disease. Additionally, the presence of metastatic disease in any other accompanying organs would be considered pM1 disease for the purpose of the TNM system.17

H. Margins
In a partial nephrectomy specimen, the renal parenchymal margin should be inked and histologically assessed.16 Most partial nephrectomy specimens also contain a portion of perinephric fat overlying the tumor site. The perirenal fat margin should also be assessed. In situations where no perirenal fat is present, the renal capsular margin should be inked and examined histologically.16
In radical nephrectomy specimens the ureteric, major vascular (renal vein, renal artery) and soft tissue (Gerota’s fascia, renal sinus) margins should be examined and documented in the report.

I. TNM and Stage Groupings
The TNM staging system of the American Joint Committee on Cancer (AJCC) for renal cell carcinoma is recommended.\textsuperscript{17}

By AJCC convention, the designation “T” refers to a primary tumor that has not been previously treated. The symbol “p” refers to the pathologic classification of the TNM, as opposed to the clinical classification, and is based on gross and microscopic examination. pT entails a resection of the primary tumor or biopsy adequate to evaluate the highest pT category, pN entails removal of nodes adequate to validate lymph node metastasis, and pM implies microscopic examination of distant lesions. Clinical classification (cTNM) is usually carried out by the referring physician before treatment during initial evaluation of the patient or when pathologic classification is not possible.

Pathologic staging is usually performed after surgical resection of the primary tumor. Pathologic staging depends on pathologic documentation of the anatomic extent of disease, whether or not the primary tumor has been completely removed. If a biopsied tumor is not resected for any reason (eg, when technically unfeasible) and if the highest T and N categories or the M1 category of the tumor can be confirmed microscopically, the criteria for pathologic classification and staging have been satisfied without total removal of the primary cancer.

Stage Groupings

<table>
<thead>
<tr>
<th>Stage</th>
<th>T</th>
<th>N</th>
<th>M</th>
</tr>
</thead>
<tbody>
<tr>
<td>Stage I</td>
<td>T1</td>
<td>N0</td>
<td>M0\textsuperscript{#}</td>
</tr>
<tr>
<td>Stage II</td>
<td>T2</td>
<td>N0</td>
<td>M0</td>
</tr>
<tr>
<td>Stage III</td>
<td>T1 or T2</td>
<td>N1</td>
<td>M0</td>
</tr>
<tr>
<td></td>
<td>T3</td>
<td>N0 or N1</td>
<td>M0</td>
</tr>
<tr>
<td>Stage IV</td>
<td>T4</td>
<td>Any N</td>
<td>M0</td>
</tr>
<tr>
<td></td>
<td>Any T</td>
<td>Any N</td>
<td>M1</td>
</tr>
</tbody>
</table>

\textsuperscript{#} M0 is defined as no distant metastasis.

TNM Descriptors

For identification of special cases of TNM or pTNM classifications, the “m” suffix and “y,” “r,” and “a” prefixes are used. Although they do not affect the stage grouping, they indicate cases needing separate analysis.

The “m” suffix indicates the presence of multiple primary tumors in a single site and is recorded in parentheses: pT(m)NM.

The “y” prefix indicates those cases in which classification is performed during or following initial multimodality therapy (ie, neoadjuvant chemotherapy, radiation therapy, or both chemotherapy and radiation therapy). The cTNM or pTNM category is identified by a “y” prefix. The ycTNM or ypTNM categorizes the extent of tumor actually present at the time of that examination. The “y” categorization is not an estimate of tumor prior to multimodality therapy (ie, before initiation of neoadjuvant therapy).

The “r” prefix indicates a recurrent tumor when staged after a documented disease-free interval, and is identified by the “r” prefix: rTNM.

The “a” prefix designates the stage determined at autopsy: aTNM.

Additional Descriptors

Residual Tumor (R)
Tumor remaining in a patient after therapy with curative intent (eg, surgical resection for cure) is categorized by a system known as R classification, shown below.
RX Presence of residual tumor cannot be assessed
R0 No residual tumor
R1 Microscopic residual tumor
R2 Macroscopic residual tumor

For the surgeon, the R classification may be useful to indicate the known or assumed status of the completeness of a surgical excision. For the pathologist, the R classification is relevant to the status of the margins of a surgical resection specimen. That is, tumor involving the resection margin on pathologic examination may be assumed to correspond to residual tumor in the patient and may be classified as macroscopic or microscopic according to the findings at the specimen margin(s).

**Lymphovascular Invasion**

By AJCC convention, vessel invasion (lymphatic or venous) does not affect the T category indicating local extent of tumor unless specifically included in the definition of a T category. In all other cases, lymphatic and venous invasion by tumor are coded separately.

**J. Pathologic Findings in Nonneoplastic Kidney**

It is important to recognize that medical kidney diseases may be present in nonneoplastic renal tissue in nephrectomy and nephroureterectomy specimens. Arterionephrosclerosis (or hypertensive nephropathy) and diabetic nephropathy are seen in approximately 30% and 20% of cases, respectively. Other medical renal diseases that have been identified include thrombotic microangiopathy, focal segmental glomerulosclerosis, and IgA nephropathy. The findings of greater than 20% global glomerulosclerosis or advanced diffuse diabetic glomerulosclerosis are predictive of significant decline in renal function 6 months after radical nephrectomy. Evaluation for medical renal disease should be performed in each case; PAS and/or Jones methenamine silver stains should applied if necessary. Consultation with a nephropathologist should be pursued as needed.

However, no studies have specifically measured peritumoral-related changes in the renal cortex. Some tumors have no peritumoral changes. Oncocytoma is the best example. While some large tumors often have a large zone of peritumoral changes compared with smaller tumors. The pseudocapsule may contain sclerotic glomeruli, tubular atrophy and show fibrointimal thickening of arteries, followed by a zone of several millimeters of acute tubular injury, none of which is representative of the cortex elsewhere. A judgement whether the amount of nonneoplastic renal parenchyma is sufficient for evaluation of medical kidney diseases should be made on a case by case basis. Two studies have used 1 mm to 5 mm as the cut-off for insufficient renal parenchyma. Five millimeters of nonneoplastic renal parenchyma is a reasonable recommendation.

**References**


The College of American Pathologists (CAP) does not permit reproduction of any substantial portion of these protocols without its written authorization. The CAP hereby authorizes use of these protocols by physicians and other health care providers in reporting on surgical specimens, in teaching, and in carrying out medical research for nonprofit purposes. This authorization does not extend to reproduction or other use of any substantial portion of these protocols for commercial purposes without the written consent of the CAP.

The CAP also authorizes physicians and other health care practitioners to make modified versions of the Protocols solely for their individual use in reporting on surgical specimens for individual patients, teaching, and carrying out medical research for non-profit purposes.

The CAP further authorizes the following uses by physicians and other health care practitioners, in reporting on surgical specimens for individual patients, in teaching, and in carrying out medical research for non-profit purposes: (1) **Dictation** from the original or modified protocols for the purposes of creating a text-based patient record on paper, or in a word processing document; (2) **Copying** from the original or modified protocols into a text-based patient record on paper, or in a word processing document; (3) The use of a **computerized system** for items (1) and (2), provided that the protocol data is stored intact as a single text-based document, and is not stored as multiple discrete data fields.

Other than uses (1), (2), and (3) above, the CAP does not authorize any use of the Protocols in electronic medical records systems, pathology informatics systems, cancer registry computer systems, computerized databases, mappings between coding works, or any computerized system without a written license from the CAP.

Any public dissemination of the original or modified protocols is prohibited without a written license from the CAP.

The CAP developed these protocols as an educational tool to assist pathologists in the useful reporting of relevant information. It did not issue the protocols for use in litigation, reimbursement, or other contexts. Nevertheless, the College recognizes that the protocols might be used by hospitals, attorneys, payers, and others. Indeed, effective January 1, 2004, the Commission on Cancer of the American College of Surgeons mandated the use of the required data elements of the protocols as part of its Cancer Program Standards for Approved Cancer Programs. Therefore, it becomes even more important for pathologists to familiarize themselves with these documents. At the same time, the CAP cautions that use of the protocols other than for their intended educational purpose may involve additional considerations that are beyond the scope of this document.

The inclusion of a product name or service in a CAP publication should not be construed as an endorsement of such product or service, nor is failure to include the name of a product or service to be construed as disapproval.